Hong Kong SPAC nix­es di­ag­nos­tics merg­er; Clay Sie­gall will run a pub­lic biotech again

HH&L Ac­qui­si­tion Co., a SPAC that went through a $360 mil­lion IPO in ear­ly 2021, has re­neged on its busi­ness com­bi­na­tion agree­ment.

The Hong Kong-based blank check pulled plans to take Cal­i­for­nia mol­e­c­u­lar di­ag­nos­tics com­pa­ny Di­aCar­ta pub­lic via a merg­er. In an SEC fil­ing, HH&L said it ter­mi­nat­ed the deal last week, “based on breach­es by Di­aCar­ta of cer­tain rep­re­sen­ta­tions and covenants con­tained in the busi­ness com­bi­na­tion agree­ment and fraud­u­lent mis­rep­re­sen­ta­tion on the part of Di­aCar­ta.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER